Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases.

Details

Serval ID
serval:BIB_8D5FC967934E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases.
Journal
Modern pathology
Author(s)
Sarro R., Bisig B., Guey B., Missiaglia E., Cairoli A., Omoumi P., Letovanec I., Ferry J.A., Hasserjian R.P., de Leval L.
ISSN
1530-0285 (Electronic)
ISSN-L
0893-3952
Publication state
Published
Issued date
04/2024
Peer-reviewed
Oui
Volume
37
Number
4
Pages
100440
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Primary bone lymphoma (PBL) is rare and mostly represented by diffuse large B-cell lymphomas (DLBCL). Follicular lymphoma (FL), albeit commonly disseminating to the bone marrow, rarely presents primarily as bone lesions. Here, we studied 16 patients (12 men:4 women, median age 60 years) who presented with bone pain and/or skeletal radiologic abnormalities revealing bone FL. Lesions were multifocal in 11 patients (spine ± appendicular skeleton), and unifocal in 5 patients (femoral, tibial, or vertebral). An infiltrate of centrocytes and centroblasts (CD20+ CD5- CD10+ BCL2+ BCL6+) with abundant reactive T cells and an increased reticulin fibrosis massively replaced the marrow spaces between preserved bone trabeculae. The pattern was diffuse ± nodular, often with paratrabecular reinforcement and/or peripheral paratrabecular extension. Ki-67 was usually <15%. Two cases had necrosis. BCL2 rearrangement was demonstrated in 14 of 14 evaluable cases (with concomitant BCL6 rearrangement in one). High-throughput sequencing revealed BCL2, KMT2D, and TNFRSF14 to be the most frequently mutated genes. After staging, 5 qualified for PBL (3 limited stage) and 11 had stage IV systemic FL. All patients received rituximab ± polychemotherapy as firstline treatment, and 7 received local therapy (6 radiotherapy and 2 surgery). Three patients experienced transformation to DLBCL. At the last follow-up (15/16, median 48 months), 11 patients achieved complete remission, including all cases with PBL and most patients with limited extraosseous disease (3-year progression-free survival 71%). One patient died of unrelated cause (3-year overall survival 91%). FL may manifest as a localized or polyostotic bone disease. A minority represent PBL, whereas most reveal systemic disease.
Keywords
Male, Humans, Female, Middle Aged, Lymphoma, Follicular/genetics, Lymphoma, Follicular/therapy, Lymphoma, Follicular/pathology, Lymphoma, Large B-Cell, Diffuse/pathology, Rituximab, Progression-Free Survival, Proto-Oncogene Proteins c-bcl-2/genetics, BCL2 rearrangement, bone lymphoma, follicular lymphoma, mutational profile
Pubmed
Web of science
Create date
01/02/2024 16:32
Last modification date
23/04/2024 6:59
Usage data